AU2018202623A1 - Oxalate salts of Teneligliptin and solvates thereof, intermediates, process of prepration and markers thereof - Google Patents

Oxalate salts of Teneligliptin and solvates thereof, intermediates, process of prepration and markers thereof Download PDF

Info

Publication number
AU2018202623A1
AU2018202623A1 AU2018202623A AU2018202623A AU2018202623A1 AU 2018202623 A1 AU2018202623 A1 AU 2018202623A1 AU 2018202623 A AU2018202623 A AU 2018202623A AU 2018202623 A AU2018202623 A AU 2018202623A AU 2018202623 A1 AU2018202623 A1 AU 2018202623A1
Authority
AU
Australia
Prior art keywords
oxalate
teneligliptin
salt
hydrate
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018202623A
Other languages
English (en)
Inventor
Shekhar Bhaskar Bhirud
Rajesh Kumar DWIVEDI
Suresh Mahadev Kadam
Shrikrishna Kantilal KALE
Bipin Parsottam Kansagra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glenmark Pharmaceuticals Ltd
Original Assignee
Glenmark Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63039388&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2018202623(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glenmark Pharmaceuticals Ltd filed Critical Glenmark Pharmaceuticals Ltd
Publication of AU2018202623A1 publication Critical patent/AU2018202623A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
AU2018202623A 2017-02-03 2018-02-02 Oxalate salts of Teneligliptin and solvates thereof, intermediates, process of prepration and markers thereof Abandoned AU2018202623A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201721004095 2017-02-03
IN201721004095 2017-02-03
PCT/IB2018/050652 WO2018142327A1 (en) 2017-02-03 2018-02-02 Oxalate salts of teneligliptin and solvates thereof, intermediates, process of preparation

Publications (1)

Publication Number Publication Date
AU2018202623A1 true AU2018202623A1 (en) 2018-08-23

Family

ID=63039388

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018202623A Abandoned AU2018202623A1 (en) 2017-02-03 2018-02-02 Oxalate salts of Teneligliptin and solvates thereof, intermediates, process of prepration and markers thereof
AU2018202960A Abandoned AU2018202960A1 (en) 2017-02-03 2018-02-02 Formulations comprising oxalate salts of Teneligliptin and solvates thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2018202960A Abandoned AU2018202960A1 (en) 2017-02-03 2018-02-02 Formulations comprising oxalate salts of Teneligliptin and solvates thereof

Country Status (10)

Country Link
JP (2) JP2019512460A (pt)
KR (2) KR20180100554A (pt)
CN (2) CN108697707A (pt)
AU (2) AU2018202623A1 (pt)
BR (2) BR112018010759A2 (pt)
EA (1) EA039402B1 (pt)
MX (2) MX2018006006A (pt)
RU (2) RU2742418C1 (pt)
TW (2) TW201831473A (pt)
WO (2) WO2018142334A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2020209350A1 (pt) * 2019-04-12 2020-10-15
CN110028496A (zh) * 2019-04-26 2019-07-19 梯尔希（南京）药物研发有限公司 一种特力利汀相关杂质的合成方法
WO2021053564A1 (en) * 2019-09-17 2021-03-25 Glenmark Pharmaceuticals Limited Pharmaceutical composition comprising remogliflozin or salt or ester thereof and teneligliptin or salt thereof
KR20210121421A (ko) 2020-03-30 2021-10-08 코오롱생명과학 주식회사 테네리글리프틴 2.5브롬화수소산염 무정형의 제조방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI319322B (en) * 2003-11-13 2010-01-11 Ono Pharmaceutical Co Frozen-dried preperation containing prostaglandin
CN102372704B (zh) * 2005-02-18 2014-10-08 田边三菱制药株式会社 脯氨酸衍生物的盐，其溶剂合物，及其生产方法
KR20160143897A (ko) * 2009-02-13 2016-12-14 베링거 인겔하임 인터내셔날 게엠베하 Ｄｐｐ－４ 억제제(리나글립틴)을 임의로 다른 당뇨병 치료제와 병용하여 포함하는 당뇨병 치료 약제
MX364651B (es) * 2009-11-27 2019-05-03 Boehringer Ingelheim Int Gmbh Star Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmacéuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabéticos tipificados genéticamente.
TWI418370B (zh) * 2009-12-18 2013-12-11 Mitsubishi Tanabe Pharma Corp 溶出安定性製劑
US9518048B2 (en) * 2012-08-31 2016-12-13 Glenmark Pharmaceuticals Limited Process for the preparation of teneligliptin
JP6088872B2 (ja) * 2013-03-22 2017-03-01 サラヤ株式会社 ラクトン型ソホロリピッドの分解が抑制されたソホロリピッド粉末
WO2015012365A1 (ja) * 2013-07-25 2015-01-29 株式会社 三和化学研究所 医薬製剤
WO2015019238A1 (en) * 2013-08-06 2015-02-12 Ranbaxy Laboratories Limited Process for the preparation of n-protected (5s)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-one
CN104650065A (zh) * 2013-11-22 2015-05-27 天津市汉康医药生物技术有限公司 一种替格列汀化合物
WO2015132679A1 (en) * 2014-03-05 2015-09-11 Glenmark Pharmaceuticals Ltd Teneligliptin compositions
WO2015173779A1 (en) * 2014-05-16 2015-11-19 Micro Labs Limited Process for the preparation of teneligliptin and its novel intermediates
CN105294673B (zh) * 2014-06-18 2018-04-13 四川科伦药物研究院有限公司 一种氢溴酸替格列汀的合成方法
WO2016051368A1 (en) * 2014-10-01 2016-04-07 Mylan Laboratories Ltd Complex of amorphous empagliflozin and a cyclodextrin
JP6027710B1 (ja) * 2014-12-25 2016-11-16 田辺三菱製薬株式会社 糖尿病治療用固形製剤

Also Published As

Publication number Publication date
JP2019508385A (ja) 2019-03-28
KR20180099635A (ko) 2018-09-05
WO2018142327A1 (en) 2018-08-09
JP2019512460A (ja) 2019-05-16
CN108697707A (zh) 2018-10-23
MX2018006006A (es) 2019-05-16
BR112018010748A2 (pt) 2018-12-04
KR20180100554A (ko) 2018-09-11
TW201831473A (zh) 2018-09-01
RU2742418C1 (ru) 2021-02-05
BR112018010759A2 (pt) 2018-12-04
WO2018142334A1 (en) 2018-08-09
EA201992376A1 (ru) 2020-03-23
RU2018120216A (ru) 2021-05-07
MX2018006005A (es) 2019-05-16
EA039402B1 (ru) 2022-01-24
TW201834655A (zh) 2018-10-01
CN108884089A (zh) 2018-11-23
AU2018202960A1 (en) 2018-08-23

Similar Documents

Publication Publication Date Title
AU2018202623A1 (en) Oxalate salts of Teneligliptin and solvates thereof, intermediates, process of prepration and markers thereof
US9440959B2 (en) Process for the preparation of nilotinib
EP2909191B1 (en) Multicomponent crystalline system comprising nilotinib and selected co-crystal formers
EP3022209B1 (en) Dolutegravir potassium salt
WO2016131431A1 (en) Solid forms of empagliflozin
US7393977B2 (en) Dicarboxylic acid salt of sibutramine
WO2022033380A1 (zh) 一种mor受体激动剂化合物、制备方法及其用途
US20030191347A1 (en) Venlafaxine base
US20160176832A1 (en) Crystalline forms of neurotrophin mimetic compounds and their salts
EP2626355B1 (en) Process for the preparation of nilotinib hydrochloride
KR102442536B1 (ko) 리나글립틴 결정형 및 이의 제조방법
US11225467B2 (en) Crystalline forms of neurotrophin mimetic compounds and their salts
US10519150B2 (en) Salts of morpholine derivative, crystal forms thereof, processes for producing the same, pharmaceutical compositions including the same, and use thereof
US20230219892A1 (en) Forms and compositions of a beta adrenergic agonist
EP3650444B1 (en) Salt and polymorph of benzopyrimidinone compound and pharmaceutical composition and use thereof
AU2012277403A1 (en) Novel salts of sitagliptin
WO2005030698A1 (en) Process for the preparation of voglibose
WO2022224269A1 (en) Co-crystals, salts and solid forms of niraparib
US8569289B2 (en) Fumarate salt of 4-bromophenyl 1,4-diazabicyclo[3.2.2]nonane-4-carboxylate, crystalline forms thereof, preparation thereof and therapeutic use thereof
WO2021208850A1 (zh) 硝基咪唑类衍生物及其制备方法和用途
KR20200068667A (ko) 고체 형태의 스테모스피로닌 및 이의 염
WO2012088647A1 (zh) 西他列汀的氘代酸加成盐
CZ200911A3 (cs) Nová forma desvenlafaxinu a zpusob její prípravy
WO2014147641A2 (en) Sitagliptin pterostilbene phosphate salt, process for the preparation and pharmaceutical composition thereof

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted